

Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease

Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS.

Archives of general psychiatry

2007; 64(11):1259-1268

ARTICLE IDENTIFIERS

DOI: 10.1001/archpsyc.64.11.1259

PMID: 17984395

PMCID: not available

JOURNAL IDENTIFIERS

LCCN: not available

pISSN: 0003-990X

eISSN: 1538-3636

OCLC ID: not available

CONS ID: not available

US National Library of Medicine ID: not available

This article was identified from a query of the SafetyLit database.